Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular dystrophy.

Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping. DMD is a genetic disease that causes progressive muscle weakness and degeneration caused by a mutation in the dystrophin gene.

Wave Life Sciences has announced positive interim data from the ongoing Phase II FORWARD-53 study of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.

Wave Life Sciences (NASDAQ:WVE) added ~8% premarket Tuesday after the RNA therapeutics company announced interim data from a Phase 2 trial for WVE-N531, an experimental therapy for a neuromuscular disorder known as Duchenne muscular dystrophy (DMD).

Shares in Wave rose 53% after the trial data was announced, taking its market cap above the $1 billion threshold. The company has moved swiftly ahead with a public offering, seeking to raise an estimated $175 million as it moves towards possible commercialisation of WVE-N531.

Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531. Explore more details here.